Kathleen M. Welch - Concepedia

Author

Kathleen M. Welch

Pfizer (United States)

Also Known As

K M Welch, K. M. WELCH, K. M. Welch, K. M.A. Welch, K.M. WELCH, K.M. Welch, Kathleen M. Welch, Kathleen Welch

Publications

667

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)University of Alberta University of Michigan Io Therapeutics (United States)Warner University

About

Kathleen M. Welch is an author at Pfizer (United States) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	385
2	Biochemistry	10	10	307
3	Natural Sciences	4	4	116
4	Health Sciences	1	1	88
5	Public Health	1	1	17

Kathleen M. Welch

Publications

636

Citations

H-Index

Page 1

	Year	Citations
Human focal cerebral ischemia: evaluation of brain pH and energy metabolism with P-31 NMR spectroscopy. Steven R. Levine, J.A. Helpern, Kathleen M. Welch, Radiology Early AcidosisCerebrovascular DiseaseCerebral Vascular RegulationStrokeNeurology	1992	88
Acute elevation and recovery of intracellular [Mg <sup>2+</sup> ] following human focal cerebral ischemia J.A. Helpern, Anders Linde, Kathleen M. Welch, Neurology	1993	74
Pharmacological characterization of PD 156707, an orally active ETA receptor antagonist. Elwood E. Reynolds, Joan A. Keiser, Stephen J. Haleen, Journal of Pharmacology and Experimental Therapeutics	1995	71
In Vitro and In Vivo Studies with a Series of Hexapeptide Endothelin Antagonists Annette M. Doherty, Wayne L. Cody, J. X. He, Journal of Cardiovascular Pharmacology	1993	64
Structure−Activity Relationships in a Series of Orally Active γ-Hydroxy Butenolide Endothelin Antagonists William C. Patt, Jeremy J. Edmunds, Joseph T. Repine, Journal of Medicinal Chemistry Selective Antagonist Pd155080Pharmaceutical ScienceChemical BiologyExperimental PharmacologyMolecular Pharmacology	1997	46
The Discovery of (2<i>R</i>,4<i>R</i>)‐<i>N</i>‐(4‐chlorophenyl)‐<i>N</i>‐ (2‐fluoro‐4‐(2‐oxopyridin‐1(2<i>H</i>)‐yl)phenyl)‐4‐methoxypyrrolidine‐1,2‐dicarboxamide (PD 0348292), an Orally Efficacious Factor Xa Inhibitor Jeffrey T. Kohrt, Christopher F. Bigge, John W. Bryant, Chemical Biology & Drug Design Pharmaceutical SciencePharmacotherapyChemical BiologyPharmaceutical ChemistryMolecular Pharmacology	2007	39
Pharmacological Differences Between Rat and Human Endothelin B Receptors Elwood E. Reynolds, O. Hwang, Mary Flynn, Biochemical and Biophysical Research Communications Molecular PharmacologyMedicinePhysiologyVascular BiologyExperimental Pharmacology	1995	29
Structure-activity relationships of the potent combined endothelinA/endothelinB receptor antagonist Ac-DDip16-Leu-Asp-Ile-Ile-Trp21 (PD 142893): development of endothelinB receptor selective antagonists Wayne L. Cody, John X. He, P. L. DePue, Journal of Medicinal Chemistry Signal TransductionBiochemistryReceptor AffinityMedicineFunctional Selectivity	1995	24
Butenolide Endothelin Antagonists with Improved Aqueous Solubility William C. Patt, Xue‐Min Cheng, Joseph T. Repine, Journal of Medicinal Chemistry Pharmaceutical ScienceEta-selective EndothelinBiochemistryMedicineRational Drug Design	1999	24
Substituted oxazolidinones as novel NPC1L1 ligands for the inhibition of cholesterol absorption Jeffrey A. Pfefferkorn, Scott D. Larsen, Chad Van Huis, Bioorganic & Medicinal Chemistry Letters Lipid PreparationNovel Npc1l1OxysterolBiochemistryMedicine	2007	21

Page 1